Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

6414 results about "Blood lipids" patented technology

Blood lipids (or blood fats) are lipids in the blood, either free or bound to other molecules. They are mostly transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism. The concentration of blood lipids depends on intake and excretion from the intestine, and uptake and secretion from cells. Blood lipids are mainly fatty acids and cholesterol. Hyperlipidemia is the presence of elevated or abnormal levels of lipids and/or lipoproteins in the blood, and is a major risk factor for cardiovascular disease.

Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:DASSEUX JEAN LOUIS +5

Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:JEAN LOUIS DASSEUX +5

Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids

InactiveUS20080125490A1Effective pharmaceutical treatmentMinimize side effectsBiocideAnimal repellantsDyslipidemiaCoronary event
Compositions comprising omega-3 fatty acids are provided, where the compositions are useful for treating cardiovascular disease in patients suffering from chronic kidney disease (CKD), preventing its further progression, and treating underlying risk factors such as hypertension, dyslipidemia, obesity and / or diabetes. Also provided are methods of using the compositions to reduce the occurrence of or prevent major coronary events, including myocardial infarctions, in patients with CKD.
Owner:PRONOVA BIOCARE AS

Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids

Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and / or diabetes.
Owner:PRONOVA BIOCARE AS

Compositions and methods for silencing apolipoprotein c-iii expression

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
Owner:PROTIVA BIOTHERAPEUTICS

Antidiabetic bicyclic compounds

Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Owner:MERCK SHARP & DOHME LLC

Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof

InactiveUS20060211749A1Reduced dosages of PPAR agonistEffective treatmentBiocideMetabolism disorderDyslipidemiaFasting glucose
A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and / or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and / or the reduction of incidence and / or the delay of onset of diabetes.
Owner:RELIANT PHARMACEUTICALS INC

Gip analog and hybrid polypeptides with selectable properties

ActiveUS20080312157A1Increased insulin secretionDecreasing bone loss bonePeptide/protein ingredientsMetabolism disorderDyslipidemiaFeeding disability
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Bioeffective krill oil compositions

InactiveUS20080274203A1Increasing flesh colorationPromote growthBiocideMetabolism disorderInsulin resistanceAnti oxidant
This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and / or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
Owner:AKER BIOMARINE ANTARCTIC

Mao-b inhibitors useful for treating obesity

The invention provides a method of treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.
Owner:JENRIN DISCOVERY

Methods for synthesizing ether compounds and intermediates therefor

InactiveUS6410802B1Reduce cholesterol contentReduce contentNervous disorderAntipyreticThrombotic disorderEther
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS

ABCA-1 elevating compounds and methods

Disclosed are novel compounds of Formula Iuseful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the plasma of a mammal, in particular humans.
Owner:CV THERAPEUTICS INC

Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Owner:CORTENDO

Omega-3 pentaenoic acid compositions and methods of use

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases / conditions or risk factors therefore.
Owner:MATINAS BIOPHARMA

Ether compounds and compositions for cholesterol management and related uses

InactiveUS20030018013A1Reduce cholesterol contentReduce contentAntibacterial agentsBiocideThrombotic disorderEther
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS

New use for cannabinoids

The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
Owner:GW PHARMA LTD

Lady beer and production technology thereof

The invention relates to a beer produced from materials of 1-7 degree beerwort produced with a common beer production method, fresh fruit and vegetable juice, healthcare plant juice, traditional Chinese medicine extract, vitamins, a microelement mineral preparation, a foam stabilizer, and ethanol, which are blended according to a certain weight ratio. The lady beer provided by the invention has characteristics of digestion and absorbance promoting, beautifying, toxin expelling, freckle reducing, weight reducing, aging resisting, fatigue resisting, bowel loosening, constipation relieving, metabolism balancing, endocrine regulating, blood sugar reducing, and blood fat reducing. The contents of beerwort and ethanol in the beer are low. With the lady beer, original flavors of beer are preserved, abundant nutrients are provided, beer belly is not caused with long-term drinking, obesity is not caused, and a good healthcare effect is provided. The application scope of the lady beer is wide, and the lady beer is especially suitable for ladies.
Owner:张华

Five-leaf tea for reducing blood pressure, blood fat and blood sugar

The invention relates to a sally quinquefolia tea for reducing blood pressure, blood lipid and blood glucose, and is characterized in that the sally quinquefolia tea is mainly prepared from the following compositions in weight proportions : 250 to 300 portions of tea leaves, 5 to 10 portions of ginseng leaves, 3 to 6 portions of apocynum venetum (leaves), 3 to 6 portions of mulberry leaves, 3 to 6 portions of eucommia leaves, 3 to 6 portions of ginkgo leaves and 5 to 10 portions of ganoderma. The sally quinquefolia tea for reducing blood pressure, blood lipid and blood glucose is prepared scientifically with proper preparation, wherein in the blood pressure reduction aspect, the headache, dizziness and giddiness can be prevented; in the blood lipid reduction aspect, the palpitation, fatigue and bad sleep can be prevented; and in the blood glucose reduction aspect, the thirsty, emaciation and more night urine are prevented so as to prevent serious complicating diseases to the brain, the heart and the kidney. The sally quinquefolia tea has the functions of medicine, so that the health care function is obvious, colour, aroma and flavor of the original tea leaf are maintained with mellow scent, pure and sweet taste. Therefore, the sally quinquefolia tea is the best health-care functional drink for reducing blood pressure, blood lipid and blood glucose and is suitable for people who need to prevent and treat angiocardiopathy.
Owner:广东健神科技股份有限公司

Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
Owner:DASSEUX JEAN LOUIS +5

Combination therapy for the treatment of dyslipidemia

The present invention relates to compositions comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
Owner:MERCK SHARP & DOHME CORP

Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes

InactiveUS20070203521A1Ameliorate or eliminate an attendant conditionElectrotherapyDyslipidemiaAcute hyperglycaemia
A tissue modulation device, for treating at least one of obesity, metabolic syndrome, and Type 2 diabetes in a patient, is described. In some embodiments, the device includes a storage module having computer-readable instructions for delivering an electrical stimulation pattern to a splanchnic nerve of the patient. The stimulation pattern includes at least one on-time. The on-time includes at least one of a suprathreshold period and a subthreshold period. The splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve. The pattern is effective to ameliorate at least one attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition includes dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and / or insulin resistance.
Owner:ADVANCED NEUROMODULATION SYST INC

Pu'er tea extract and preparation method and application

The invention relates to a Pu'er tea extract, and a preparation method and application thereof. The Pu'er tea extract is high active ingredient content and can reduce blood sugar and blood fat obviously. By the preparation method of the Pu'er tea extract, the active ingredients are completely and effectively converted and dissolved out. The process of the Pu'er tea extract has the advantages of guaranteeing the clarity of the finished products which are dissolved in cold water and reducing investment requirement of refrigerated storage tanks and the difficulty and the work load of filtering operation due to a refrigeration process after concentration, along with low cost, industrialization and stable and controllable quality.
Owner:TIANJIN TASLY GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products